Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. MPX International's cash to debt ratio for the quarter that ended in Mar. 2022 was 0.04.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, MPX Internationalcouldn't pay off its debt using the cash in hand for the quarter that ended in Mar. 2022.
The historical rank and industry rank for MPX International's Cash-to-Debt or its related term are showing as below:
MPXOF's Cash-to-Debt is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.98 * Ranked among companies with meaningful Cash-to-Debt only.
MPX International (OTCPK:MPXOF) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
MPX International Cash-to-Debt Related Terms
MPX International Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for MPX International's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Drug Manufacturers - Specialty & Generic subindustry, MPX International's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MPX International Cash-to-Debt vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, MPX International's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where MPX International's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MPX International (MPXOF) has a Cash-to-Debt of 0.04 as of Mar. 2022.
Is MPX International's Cash-to-Debt too high?
MPX International's current Cash-to-Debt is 0.04. The Drug Manufacturers industry median Cash-to-Debt is 0.98. MPX International's value of 0.04 is 95.9% below this industry median.
How does MPX International's Cash-to-Debt compare to ZTS and CTLT?
MPX International's Cash-to-Debt of 0.04 can be compared against companies in the Drug Manufacturers industry. The industry median Cash-to-Debt is 0.98. MPX International's value of 0.04 is 95.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Drug Manufacturers company?
The median Cash-to-Debt among Drug Manufacturers companies is 0.98, based on 984 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MPX International's current Cash-to-Debt of 0.04 is 95.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Cash-to-Debt is 0.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MPX International's current Cash-to-Debt is 0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MPX International stock overvalued right now?
MPX International (MPXOF) has a current Cash-to-Debt of 0.04. The current Cash-to-Debt is 0.04 and 95.9% below the Drug Manufacturers industry median of 0.98. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For MPX International (MPXOF), the current Cash-to-Debt is 0.04 as of Mar. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MPX International Corp is a diversified cannabis company focused on developing and operating assets across the global medical and adult use and engaged in cultivating, manufacturing and marketing products that include cannabinoids as their primary active ingredient. The firm is organized into three segments: Canada, Europe/Africa, and Asia-Pacific. The Canada operating segment's principal business activities consist of production and sale of cannabis, video learning and engagement, patient counselling and referral services. The Europe/Africa operating segment's consist of the production and sale of cannabis and hemp-related products. The Asia-Pacific consist of the production and sale of cannabis. The majority of the revenue is generated in Canada.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MPXOF has been successfully added to your 
